Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. But so far, the company is ...

A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Just nine months after announcing a hefty plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money. The new plan, which has been dubbed a ...

Revenue: US$48.3b (up 7.3% from FY 2023). Net loss: US$8.95b (down by 212% from US$8.03b profit in FY 2023). US$4.41 loss per share (down from US$3.88 profit in FY 2023). Revenue exceeded analyst ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag ...

Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Bristol Myers Squibb posted Q4 revenue of $12.34B, beating the consensus, with an 8% YoY increase driven by Growth Portfolio and Eliquis. Adjusted EPS was $1.67, topping the $1.46 consensus but ...

Bristol Myers Squibb will cut $2 billion in costs by the end of 2027, a move aimed at long-term growth as the company prepares for patent expirations on key treatments, CNBC reported Feb. 6.

A viewer called to ask about Bristol-Myers Squibb Company (NYSE:BMY) and if they should hold it. This is what Cramer had to say: “No, no, you don’t hold it. You buy more. This COBENFY is this ...

(RTTNews) - While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2025.